Longeviti key facts
as of Oct 2026- Operaror of a neuro-technology company intended to innovate manufacturing and globally distribute functional neurosurgical implants for complex brain surgeries.
- Longeviti is valued at approximately $110.0M as of Oct 2026 (last reported valuation).
- It has raised $38.8M; the latest was Later Stage VC ($10.0M) in Aug 2025.
- Notable investors include TEDCO, Soleus Capital, Abell Foundation, Ecphora Capital, Blueprint Medtech — 7 tracked in total.
- Status: Privately Held (backing).
Longeviti's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·Watch Longeviti: the Monday email on marks, rounds and moves
Longeviti funding rounds
No funding rounds for Longeviti are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Longeviti valuation
Longeviti's last reported valuation was $110 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
Longeviti investors
7 investors are on record for Longeviti, including TEDCO, Soleus Capital, Abell Foundation and Ecphora Capital.
About Longeviti
Operaror of a neuro-technology company intended to innovate manufacturing and globally distribute functional neurosurgical implants for complex brain surgeries. The company's products provide space within the brain or skull to fit lifesaving neuro technologies, including valves, brain-computer interface, drains, intracranial pressure diagnostics, and blood brain barrier BBB drug delivery capabilities, enabling healthcare practitioners and patients to retrieve lifesaving neuro information in seconds and real-time, versus traditional imaging and diagnostic methods.
- Sector
- Healthcare
- HQ
- Hunt Valley, MD, United States
- Founded
- 2016
- Employees
- 44
- Website
- longeviti.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.